Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Results from clinical trials have demonstrated that it is possible to prevent estrogen-responsive breast cancers by targeting the estrogen receptor with selective estrogen receptor modulators (SERMs) (tamoxifen, raloxifene, or lasofoxifene) or with aromatase inhibitors (AIs) (anastrozole, letrozole, or exemestene). Results from breast cancer treatment trials suggest that aromatase inhibitors may be even more effective in preventing breast cancer than SERMs. However, while SERMs and aromatase inhibitors do prevent the development of many ER-positive breast cancers, these drugs do not prevent ER-negative breast cancer. These results show that new approaches are needed for the prevention of this aggressive form of breast cancer. Our laboratory and clinical efforts have been focused on identifying critical molecular pathways in breast cells that can be targeted for the prevention of ER-negative breast cancer. Our preclinical studies have demonstrated that other nuclear receptors, such as RXR receptors, vitamin D receptors, as well as others are critical for the growth of ER-negative breast cells and for the transformation of these cells into ER-negative cancers. Other studies show that growth factor pathways including those activated by EGFR, Her2, and IGFR, which are activated in many ER-negative breast cancers, can be targeted for the prevention of ER-negative breast cancer in mice. Clinical studies have also shown that PARP inhibitors are effective for the treatment of breast cancers arising in BRCA-1 or -2 mutation carriers, suggesting that targeting PARP may also be useful for the prevention of breast cancers arising in these high-risk individuals. Most recently, we have demonstrated that ER-negative breast cancers can be subdivided into four distinct groups based on the kinases that they express. These groups include ER-negative/Her-2-positive groups (the MAPK and immunomodulatory groups) and ER-negative/Her2-negative groups (the S6K and the cell cycle checkpoint groups). These groups of ER-negative breast cancers can be targeted with kinase inhibitors specific for each subgroup. These preclinical studies have supported the development of several clinical trials testing targeted agents for the prevention of breast cancer. The results of a completed Phase II cancer prevention trial using the RXR ligand bexarotene in women at high risk of breast cancer will be reviewed, and the current status of an ongoing Phase II trial using the EGFR and Her2 kinase inhibitor lapatinib for the treatment of women with DCIS breast cancer will be presented. It is anticipated that in the future these molecularly targeted drugs will be combined with hormonal agents such as SERMs or aromatase inhibitors to prevent all forms of breast cancer.
Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230, USA.
Iván P
IP
Uray
Powel H
PH
Brown
D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000737:chemistry / Q000517:prevention & control*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011960:Receptors, Estrogen / Q000032:analysis*; D012176:Retinoids / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D047072:Aromatase Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011960:Receptors, Estrogen; D012176:Retinoids; D020845:Selective Estrogen Receptor Modulators; D008687:Metformin
J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
16288118
Recent Results Cancer Res. 2003;163:96-103; discussion 264-6
12903846
J Clin Oncol. 2005 Dec 1;23(34):8606-12
16260694
Oncogene. 2004 Jun 3;23(26):4614-23
15064713
Int J Cancer. 2007 Aug 15;121(4):856-62
17397032
Cancer Res. 2002 Oct 1;62(19):5405-7
12359744
JAMA. 2006 Jun 21;295(23):2727-41
16754727
J Natl Cancer Inst. 2007 May 2;99(9):727-37
17470740
J Natl Cancer Inst. 2009 Jan 21;101(2):107-13
19141783
Anticancer Agents Med Chem. 2009 May;9(4):457-70
19442044
N Engl J Med. 2010 Feb 25;362(8):686-96
20181970
Cancer Res. 2005 Apr 15;65(8):3462-9
15833882
Ann Oncol. 2009 Mar;20(3):592-5
19153119
Nat Rev Cancer. 2005 May;5(5):341-54
15864276
Cancer Prev Res (Phila). 2009 Feb;2(2):168-74
19174577
Breast J. 2005 Jul-Aug;11(4):278-80
15982396
Breast. 2009 Aug;18 Suppl 2:S1-11
19712865
J Exp Med. 1925 Nov 30;42(6):753-77
19869087
Cancer Res. 1999 Nov 15;59(22):5671-3
10582681
Exp Cell Res. 1999 Jul 10;250(1):22-34
10388518
Clin Cancer Res. 2006 Oct 1;12(19):5902-9
17020999
Ann N Y Acad Sci. 2009 Feb;1155:141-61
19250201
Cancer Res. 2002 Nov 15;62(22):6376-80
12438218
Lancet. 1985 Aug 3;2(8449):282
2862460
Br J Surg. 2001 Mar;88(3):412-8
11260109
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):701-5
19240238
Am J Clin Nutr. 2007 Sep;86(3):s823-35
18265476
Cancer Res. 2004 May 15;64(10):3566-71
15150113
N Engl J Med. 2009 Jul 9;361(2):123-34
19553641
J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33
14679152
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1028-33
18463402
Int J Cancer. 2004 Dec 20;112(6):909-19
15316938
J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
9747868
Breast. 2010 Apr;19(2):76-83
20096578
Cancer Prev Res (Phila). 2010 Mar;3(3):312-21
20145191
J Endocrinol Invest. 1996 May;19(5):324-33
8796343
J Clin Oncol. 2005 Jan 10;23(2):254-66
15637389
Nature. 2005 Apr 14;434(7035):913-7
15829966
Clin Cancer Res. 2009 Jan 1;15(1):226-37
19118050
Annu Rev Med. 2002;53:35-57
11818462
Gastroenterology. 2000 Dec;119(6):1447-53
11113065
Lancet Oncol. 2008 Jan;9(1):45-53
18083636
Mol Cell. 1998 Feb;1(3):465-70
9660931
Breast Cancer Res Treat. 2006 Mar;96(2):147-57
16273314
Endocrinology. 1958 Sep;63(3):295-318
13574085
Cell Death Differ. 2004 Dec;11 Suppl 2:S126-43
15608692
Ann N Y Acad Sci. 2001 Dec;949:345-8
11795374
Cancer Res. 2006 Sep 1;66(17):8707-14
16951186
J Clin Oncol. 2009 Jul 10;27(20):3271-3
19487373
Cell Growth Differ. 1996 Aug;7(8):997-1004
8853895
Breast Cancer Res Treat. 2010 Jan;119(1):137-44
19728082
Br J Cancer. 2001 May 4;84(9):1188-92
11336469
Cancer Res. 2006 Nov 1;66(21):10269-73
17062558
J Pharmacol Exp Ther. 2005 Jul;314(1):1-8
15805430
Circulation. 2004 Jun 1;109(21 Suppl 1):II34-41
15173061
J Natl Cancer Inst. 2000 Mar 1;92(5):418-23
10699072
Cancer Res. 2001 Dec 15;61(24):8887-95
11751413
Anticancer Res. 1999 Jan-Feb;19(1B):731-40
10216485
Carcinogenesis. 1999 Oct;20(10):1905-11
10506103
Cell Growth Differ. 1997 Jun;8(6):631-41
9185997
N Engl J Med. 2002 Feb 28;346(9):683-93
11870247
Menopause. 2003 Jul-Aug;10(4):332-6
12851516
J Clin Oncol. 2006 May 1;24(13):2127; author reply 2127-8
16648516
JAMA. 1999 Jun 16;281(23):2189-97
10376571
Blood. 2002 May 15;99(10):3530-9
11986204
N Engl J Med. 1996 Feb 29;334(9):574-9
8569826
J Clin Oncol. 2008 Feb 20;26(6):833-4
18281653
Epidemiology. 1994 Mar;5(2):138-46
8172988
Oncogene. 2001 Nov 29;20(55):8025-35
11753686
Endocr Rev. 2009 Feb;30(1):51-74
19075184
J Natl Cancer Inst. 2007 Feb 21;99(4):283-90
17312305
J Biol Chem. 2009 Jan 2;284(1):345-353
18957410
Cancer Res. 2009 Nov 15;69(22):8636-44
19887620
Clin Cancer Res. 2008 Jul 15;14(14):4556-63
18628471
Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74
12010861
J Natl Cancer Inst. 2007 Feb 21;99(4):272-82
17312304
N Engl J Med. 1990 Sep 20;323(12):795-801
2202902
Clin Breast Cancer. 2007 Dec;7(11):895-900
18269782
Cancer Res. 2006 Jul 1;66(13):6884-91
16818667
Biochem Biophys Res Commun. 2001 Sep 7;286(5):916-22
11527386
Cancer Res. 1979 Apr;39(4):1339-46
421218
Cancer Res. 2000 Apr 15;60(8):2101-3
10786667
Expert Rev Anticancer Ther. 2008 Sep;8(9):1377-85
18759690
Cancer Res. 1994 Sep 1;54(17):4614-7
8062253
Clin Cancer Res. 2007 Oct 15;13(20):6224-31
17947490
Clin Cancer Res. 2000 Sep;6(9):3696-704
10999763
Lancet. 2003 Jan 25;361(9354):296-300
12559863
Science. 2005 Dec 9;310(5754):1642-6
16308421